IL-23
Robert B Chao, MD doctorRBC
4 years 7 months ago
Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO
⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO
*⃣No serious AE
@RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century. An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA), the most common form of vasculitis in patients older than 50 years of age.
Juan Camilo Sarmiento-Monroy jcsam25
4 years 7 months ago
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Dr. John Cush RheumNow
4 years 7 months ago
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Peter Nash drpnash
4 years 7 months ago
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
Robert B Chao, MD doctorRBC
4 years 7 months ago
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC
4 years 7 months ago
DISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9
Spondyloarthritis at ACR 2020: Dr. Lianne Gensler
San Francisco-based rheumatologist Dr. Lianne Gensler examines a wide range of spondyloarthritis topics at ACR 2020, including how to join up with others interested in spondyloarthritis; enthesitis; the utility of MRI for the diagnosis for axSpA; novel treatments; and the impact of drugs on disease modification.
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
Dr. John Cush RheumNow
4 years 7 months ago
Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG
Poster Hall